Cerebrospinal Pharmacokinetic Modeling and Pharmacodynamic Simulation of High-Dose Cefazolin for Meningitis Caused by...

Area of Science:

• Pharmacokinetics and Pharmacodynamics
• Infectious Diseases
• Nephrology

Background:

• Cefazolin is increasingly used for central nervous system infections caused by methicillin-susceptible Staphylococcus aureus (MSSA).
• This approach aims to reduce side effects associated with existing anti-staphylococcal drugs.
• Developing a cerebrospinal pharmacokinetic (PK) model is essential for optimizing cefazolin dosing in MSSA meningitis.

Purpose of the Study:

• To develop a cerebrospinal pharmacokinetic (PK) model for predicting cefazolin concentrations in cerebrospinal fluid (CSF).
• To individualize cefazolin dosing regimens for patients with MSSA meningitis.
• To estimate the probability of achieving PK/pharmacodynamic (PD) targets.

Main Methods:

• A hybrid approach was used to develop a cerebrospinal PK model incorporating literature data.
• Pharmacokinetic/pharmacodynamic (PK/PD) targets were defined as 100% time above the minimum inhibitory concentration (T > MIC) in CSF.
• The CSF/serum ratio was estimated from existing literature and integrated into the model.

Main Results:

• The PK/PD breakpoint MIC for continuous infusion cefazolin (6-12 g/day) reached 0.5 µg/mL in patients with creatinine clearance (CLcr) of 90 mL/min.
• This breakpoint is sufficient to inhibit 90% of the MSSA population (MIC90).
• For patients with renal dysfunction (CLcr = 30 mL/min), a reduced dose (4 g/day) is recommended to prevent excessive drug exposure.

Conclusions:

• High-dose continuous infusion cefazolin appears suitable for treating MSSA meningitis in patients with normal renal function.
• Dose adjustments are necessary for patients with impaired renal function to maintain therapeutic efficacy and safety.
• The developed PK model aids in individualizing cefazolin dosage for MSSA meningitis.